Affinivax Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 68
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $226M
Latest Deal Amount
  • Investors
  • 17

Affinivax General Information

Description

Operator of a vaccine development company intended to enhance the depth and breadth of protection against challenging infectious diseases. The company's vaccine development features a patented approach to achieve high-affinity binding of two key immunogenic components, polysaccharide and protein antigens so that both components are able to drive a broad and protective B-cell and T-cell immune response in a single vaccine, enabling doctors to deliver polysaccharides and proteins in a single vaccine and induce a protective immune response.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 301 Binney Street
  • Suite 302
  • Cambridge, MA 02142
  • United States
+1 (617) 000-0000

Affinivax Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Affinivax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 06-Jan-2021 $226M 00000 00.000 Completed Clinical Trials - General
4. Later Stage VC (Series B) 23-Apr-2020 00000 00000 00000 Completed Clinical Trials - General
3. Early Stage VC (Series A) 05-Jan-2018 00.000 000.00 0000 Completed Clinical Trials - General
2. Early Stage VC 05-Feb-2016 $2.5M $6.5M Completed Clinical Trials - General
1. Seed Round 30-Oct-2014 $4M $4M Completed Clinical Trials - General
To view Affinivax’s complete valuation and funding history, request access »

Affinivax Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 000.00 000.00 00 000.00 00.000
Series C-1 0,000,000 00.000000 000.00 000.00 00 000.00 00
Series B 8,452,884 $0.000100 $14.22 $14.22 1x $14.22 24.55%
Series A 3,068,305 $0.000100 $2.28 $2.28 1x $2.28 8.93%
To view Affinivax’s complete cap table history, request access »

Affinivax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a vaccine development company intended to enhance the depth and breadth of protection against challenging in
Drug Discovery
Cambridge, MA
68 As of 2021
00000
0.000 0000-00-00
00000000000 00000

0000000

velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, s
0000000000000
Emeryville, CA
000 As of 0000
00000
000000000 00000

000000

enderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupi
0000 000000000
Paris, France
00 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Affinivax Competitors (18)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dynavax Technologies Corporation Emeryville, CA 000 00000 000000000 00000
000000 Corporation Paris, France 00 000.00 000000000 000.00
000000 00000000000 Formerly VC-backed Boston, MA 0000 00.000 0000 00.000
0000000 00000000 Formerly PE-Backed Meriden, CT 00 000.00 000000&0 000.00
000000 Venture Capital-Backed United Kingdom 00 000.00 0000000000 000.00
You’re viewing 5 of 18 competitors. Get the full list »

Affinivax Executive Team (9)

Name Title Board Seat Contact Info
Steven Brugger President, Chief Executive Officer & Board Member
Elizabeth Radcliffe Chief Financial Officer
Kamran Tavangar Ph.D Chief Operating Officer
Richard Malley MD Scientific Co-Founder & Board Member
Fan Zhang Founding Scientist
You’re viewing 5 of 9 executive team members. Get the full list »

Affinivax Board Members (11)

Name Representing Role Since
Andrew Hack Ph.D Bain Capital Board Member 000 0000
Bob More Self Chairman 000 0000
David Rossow Self Board Member 000 0000
Frances Heller JD Self Board of Director 000 0000
Gail Rodgers MD Affinivax Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Affinivax Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Affinivax Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BlackRock Asset Manager Minority 000 0000 000000 0
CARB-X University Minority 000 0000 000000 0
Citadel (Hedge Fund) Hedge Fund Minority 000 0000 000000 0
Cormorant Asset Management Hedge Fund Minority 000 0000 000000 0
EcoR1 Capital Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »